NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Bus. News at 9PM EDT Tonight
November 18 2014 - 2:58AM
Business Wire
NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”), a
nanomedicine company developing anti-viral drugs, reported that its
CEO, Eugene Seymour, MD, MPH, has been invited to discuss the
current Ebola outbreak and the Company’s progress on a novel
experimental Ebola drug on “The Independents”, a show on the Fox
Business News Channel (FBN) at 9PM EDT tonight, November 18th.
He will discuss some of the difficulties that could be
encountered in attempts to bring the Ebola epidemic under control.
Dr. Seymour has extensive field experience in the area of
infectious diseases. He has previously worked
on HIV/AIDS in Africa, Eastern Europe and Asia. Dr.
Seymour was interviewed on FBN regarding the Ebola crisis earlier
on September 16th, and October 7th, 2014.
The Company has signed a “Cooperative Research and Development
Agreement- Materials Transfer Agreement” (CRADA-MTA) with US Army
Medical Research Institute of Infectious Diseases (USAMRIID), as
previously reported. This agreement will enable evaluation of our
drug candidates at USAMRIID in a BSL-4 facility for biological
effectiveness and safety against the Ebola virus.
NanoViricides, Inc. now has the capability of producing
sufficient quantities of an anti-Ebola drug, after it is developed,
for combating current and future Ebola epidemics. The highly
customizable nanomedicine cGMP capable pilot scale manufacturing
facility in Shelton, CT, will be able to supply all of the
nanoviricides drug candidates in quantities needed for human
clinical trials.
The Company has recently developed and is synthesizing novel
nanoviricide drug candidates against Ebola that it believes could
lead to a successful therapeutic. These drug candidates are
designed to mimic the host cell receptor onto which the Ebola virus
binds to cause an infection. The site at which the virus binds does
not change, in spite of all the mutations a virus undergoes. Thus
the Company believes that its drug candidates would continue to
work in spite of field mutations in the virus. This is unlike
vaccines, antibodies, siRNA, antisense, and several other
therapeutic modes which a virus can readily overcome due to
mutations it acquires in the field. The current outbreak in Africa
has unequivocally demonstrated the need for such an effective,
broad-spectrum, anti-Ebola therapeutic.
More than 14,000 people in Guinea, Liberia, Mali, Nigeria,
Senegal and Sierra Leone have contracted Ebola since March,
according to the World Health Organization WHO), making this the
biggest outbreak on record. More than 5,000 people have
died, up to November 11, 2014
(http://www.who.int/csr/disease/ebola/situation-reports/en/). The
Case Fatality Rate (CFR) stands at 70%. The organization has
declared that outbreaks in Nigeria and Senegal were over. Sporadic
cases have also occurred in other countries including Spain and the
United States, related to Ebola-infected personnel brought into
those countries, and infections into local health-care workers.
However, no major outbreaks have occurred outside of West
Africa.
Currently, there are no approved drugs or vaccines against
Ebola, although some vaccines as well as some drug candidates have
entered clinical trials. Recently, WHO has announced a policy for
use of experimental drugs against Ebola to expedite drug
availability.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Anil R. Diwan,
203-937-6137info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024